Farxiga Compassionate Use and Expanded Access: What Women Need to Know

What Is Farxiga and Why Are Women Asking About Access?

Farxiga (dapagliflozin) belongs to the SGLT2 inhibitor class. It blocks the sodium-glucose cotransporter-2 in the proximal tubule of the kidney, causing the kidney to excrete glucose in urine rather than reabsorbing it. The result is lower blood glucose, modest weight loss, and, through mechanisms still being studied, significant reductions in cardiovascular and kidney events.

The FDA has approved dapagliflozin for three indications: type 2 diabetes mellitus, heart failure regardless of ejection fraction, and chronic kidney disease (CKD) to reduce the risk of kidney function decline and cardiovascular death. The DAPA-HF trial demonstrated a 26% relative risk reduction in worsening heart failure or cardiovascular death in patients with heart failure with reduced ejection fraction. The DAPA-CKD trial showed a 39% relative risk reduction in sustained decline in eGFR, end-stage kidney disease, or renal/cardiovascular death compared with placebo.

Women are asking about access for several reasons. At list price, a 30-day supply runs roughly $560 to $620. Insurance coverage varies widely. And a growing number of women with PCOS, type 2 diabetes, or early-stage CKD are being prescribed Farxiga off-label or for an approved indication yet finding the cost prohibitive. That gap between clinical evidence and real-world affordability is the subject of this article.

Why This Drug Matters Specifically for Women

Women with type 2 diabetes carry a 44% higher excess relative risk of fatal coronary heart disease compared with men with type 2 diabetes, yet they are historically underrepresented in cardiovascular outcomes trials. In the DAPA-HF trial, only about 23% of participants were women. This means some of the efficacy and safety data is extrapolated to women rather than directly established in large female-only cohorts, a limitation every prescriber and patient should understand.

Women with PCOS have insulin resistance as a core feature of the syndrome, and SGLT2 inhibitors are being studied for their effect on metabolic and hormonal markers in this population. Data here are still limited, with most trials small and short. Honest clinical communication requires naming that gap.

What Is Compassionate Use and Does It Apply to Farxiga?

Compassionate use, formally called expanded access by the FDA, is a pathway that allows patients with serious or life-threatening conditions to access investigational or approved drugs outside of a clinical trial when no comparable alternative exists. The FDA's expanded access framework covers individual patient access, intermediate-size group access, and treatment protocols.

Farxiga is FDA-approved, which changes the calculus. Compassionate use in the strictest sense applies to investigational drugs. For an approved drug like dapagliflozin, the relevant pathway is either:

1. Off-label prescribing (legal and common)
2. AstraZeneca's expanded access or patient assistance program for approved indications where cost is the barrier

Does AstraZeneca Have a Compassionate-Use Program for Farxiga?

AstraZeneca does not maintain an open-enrollment compassionate-use program for Farxiga in the way some oncology manufacturers do for unapproved agents. However, AstraZeneca has a case-by-case expanded access process for situations where a patient has a serious condition, cannot access Farxiga through commercial channels, and has exhausted other options. Requests go through AstraZeneca's medical information and expanded access contact system, and the prescribing physician initiates the request, not the patient directly.

This process is slower and less structured than a formal open program. Approval is not guaranteed. For most women seeking affordability solutions, the patient assistance and copay card routes below are faster and more reliably successful.

When Expanded Access Is the Right Route

Expanded access makes most sense when you have a serious, life-threatening condition for which Farxiga is medically necessary, no therapeutic alternative is clinically appropriate, and insurance has denied coverage after appeal. Your physician or nurse practitioner must submit a request to AstraZeneca and, if the situation involves an unapproved use in an investigational context, a submission to the FDA's expanded access portal.

AstraZeneca Patient Assistance: The AZ&Me Program

The AZ&Me Prescription Savings program is AstraZeneca's primary affordability vehicle. As of 2026, the program offers free Farxiga to qualifying patients who meet income and insurance eligibility criteria. Key features:

• Income threshold: Typically at or below 600% of the federal poverty level, though AstraZeneca adjusts thresholds periodically.
• Insurance status: Designed for uninsured or underinsured patients. Patients with government insurance (Medicare, Medicaid) have separate pathways.
• Application: Completed by the prescriber or their office staff, not the patient alone. Processing takes days to a few weeks.
• Duration: Renewed annually with income verification.

If you are a woman without insurance or with a high-deductible plan and your income falls within the threshold, AZ&Me is the most direct route to free medication. Programs change frequently, so verify current criteria at the AstraZeneca website or by calling 1-800-AZandMe.

Copay Cards and Commercial Insurance Savings

For commercially insured women, AstraZeneca's Farxiga savings card program can reduce monthly cost to as low as $10 per 30-day supply. This applies to eligible patients with commercial (private) insurance who meet program terms. Medicare and Medicaid patients are excluded from copay card use under federal anti-kickback rules.

The savings card is available at azandme.com or through your pharmacy. Some pharmacy benefit managers run their own preferred programs, so check both your insurer's formulary tier for Farxiga and the manufacturer card to stack the best benefit.

Using HSA and FSA for Farxiga

Yes, you can use a Health Savings Account (HSA) or Flexible Spending Account (FSA) to pay for Farxiga, provided you have a valid prescription for an FDA-approved indication. Prescription drugs are qualifying medical expenses under IRS Publication 502. Using pre-tax HSA or FSA dollars on a $580 monthly medication effectively reduces your real cost by your marginal tax rate, which can mean $130 to $200 in annual savings for someone in the 22-24% bracket.

If your Farxiga is prescribed off-label (for PCOS, for example), HSA/FSA reimbursement is still permitted as long as a licensed clinician has written a prescription. The IRS does not distinguish between on-label and off-label prescriptions for drug reimbursement purposes.

Generic Dapagliflozin: Is It Available Yet?

As of early 2026, no FDA-approved generic dapagliflozin is on the U.S. Market. AstraZeneca's U.S. Patent exclusivity for Farxiga has been subject to litigation, and generic manufacturers have filed applications. Patent expiry timelines shift. Check the FDA's Orange Book for the most current exclusivity and patent status, because this is the fastest-changing piece of the access picture.

When generics do arrive, price drops for SGLT2 inhibitors could be substantial, as seen with metformin and other widely-used diabetes drugs. If you are currently managing cost through the AZ&Me program or a copay card, your pharmacist can alert you when a generic becomes available and switch you automatically with prescriber authorization.

Farxiga Dosing and Women-Specific Pharmacology

The standard approved dose of dapagliflozin is 10 mg orally once daily, taken in the morning with or without food. The 5 mg dose is used only in type 2 diabetes when the lower dose is preferred for tolerability, and it is not approved for heart failure or CKD.

How Hormonal Status Changes the Picture

Women show modestly higher plasma concentrations of dapagliflozin compared with men at the same dose in pharmacokinetic studies, likely related to differences in body composition and renal tubular transport activity. This difference has not translated into a requirement for dose adjustment, but it may contribute to sex differences in adverse event rates.

Specifically, women taking SGLT2 inhibitors have a significantly higher rate of genital mycotic infections (vulvovaginal candidiasis) than men. Clinical trial data pooled across the dapagliflozin program showed genital infection rates of approximately 8-11% in women versus 3-4% in men. This is a predictable, manageable consequence of glucosuria, not a reason to avoid the drug, but it means you should discuss prophylactic or early-treatment strategies with your clinician before starting.

Urinary tract infections are also more common in women at baseline, and the glucosuria from SGLT2 inhibition creates a theoretically higher-risk environment for UTIs. Trial data have shown a modest increase in UTI rates, though the absolute increase is small. Good hygiene, adequate hydration, and prompt treatment if symptoms arise are practical countermeasures.

Women in Perimenopause and Menopause

During perimenopause and after menopause, women experience rising cardiovascular risk, changes in insulin sensitivity, and shifts in adipose distribution toward visceral fat. SGLT2 inhibitors address several of these changes simultaneously. Dapagliflozin produces modest weight loss (approximately 2-3 kg sustained over 24 weeks in trial data from the DECLARE-TIMI 58 study), reduces blood pressure by 3-5 mmHg, and reduces visceral adiposity preferentially.

For women in the menopausal transition who also have type 2 diabetes or established cardiovascular disease, dapagliflozin can reduce cardiac and renal risk. There is no clinical evidence that hormone therapy (HT) meaningfully alters dapagliflozin's efficacy or safety, but women on HT should be monitored for any blood pressure interactions, given that some formulations of HT affect sodium retention.

Women with PCOS

PCOS affects approximately 6-12% of women of reproductive age and is characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance. Several small trials have examined SGLT2 inhibitors in PCOS, showing improvements in insulin sensitivity, modest reductions in free androgen index, and weight reduction. The evidence base is not yet sufficient for a guideline recommendation. The American College of Obstetricians and Gynecologists currently recommends metformin as the primary insulin-sensitizing agent in PCOS. Dapagliflozin in PCOS is off-label; discuss the risk-benefit ratio carefully with your clinician, and use reliable contraception given the absolute contraindication in pregnancy (see below).

Pregnancy, Lactation, and Contraception: Required Reading

Farxiga is contraindicated in the second and third trimesters of pregnancy. The FDA updated labeling reflects animal data showing fetal kidney toxicity when SGLT2 inhibitors are given during the period of renal development, which in humans corresponds to the second trimester onward. The FDA drug label for dapagliflozin states: "Based on animal data showing adverse renal effects, FARXIGA is not recommended during the second and third trimesters of pregnancy."

Human data on first-trimester exposure are limited. The general clinical recommendation is to avoid dapagliflozin throughout pregnancy, switching to insulin or other agents with established pregnancy safety profiles before conception when possible.

If You Are Trying to Conceive

If you have type 2 diabetes, heart failure, or CKD and are planning pregnancy, discuss a medication switch with your care team before stopping contraception. Metformin and insulin have the most established safety records in pregnancy for diabetes management. Women with heart failure or CKD who become pregnant require specialist co-management; several cardiorenal medications must be stopped or changed before or early in pregnancy.

Women prescribed Farxiga off-label for PCOS who are actively trying to conceive should stop the medication before attempting conception and transition to a pregnancy-compatible regimen.

Lactation

Dapagliflozin is not recommended during breastfeeding. Animal studies show that SGLT2 inhibitors are present in milk and cause adverse renal effects in juvenile animals during the period of postnatal renal maturation. Human lactation data are absent. Given the potential for neonatal renal harm, the FDA label advises against use during lactation, and the clinical consensus is to avoid it while breastfeeding.

Contraception Requirements

Any woman of reproductive potential taking Farxiga for any indication should use reliable contraception. This is not a formal FDA-mandated contraception program (as exists for isotretinoin or thalidomide), but the teratogenic risk from second- and third-trimester exposure is serious enough that preventing unintended pregnancy is a clinical priority. Discuss contraceptive options with your prescriber. Combined oral contraceptives, progesterone-only pills, IUDs, and barrier methods are all compatible with dapagliflozin pharmacology; the drug does not interfere with hormonal contraceptive efficacy.

Who This Is Right For, and Who Should Avoid It

The table below organizes Farxiga eligibility by life stage and clinical context, a framework developed by the WomanRx clinical editorial team to help women and their clinicians quickly locate the relevant considerations.

| Life Stage / Condition | Farxiga Suitability | Key Caveat | |---|---|---| | Reproductive years, type 2 diabetes, not pregnant | Generally appropriate | Reliable contraception required | | Reproductive years, PCOS, not pregnant | Off-label; limited evidence | Discuss with clinician; contraception required | | Trying to conceive | Stop before attempting conception | Switch to insulin/metformin | | Pregnancy (any trimester) | Contraindicated in T2/T3; avoid in T1 | Fetal renal toxicity risk | | Postpartum, breastfeeding | Not recommended | Neonatal renal safety unknown | | Perimenopause, cardiovascular risk | Appropriate with monitoring | Watch for genital infections, UTI | | Postmenopause, HFpEF or CKD | Approved indication; strong evidence | Standard monitoring applies | | Any woman with recurrent yeast infections | Use with caution | Discuss prophylaxis plan before starting | | eGFR <25 mL/min/1.73m² | Glycemic efficacy reduced; CKD/HF benefit preserved | Check current label for eGFR cutoffs |

Other Ways to Reduce Cost: GoodRx, Mark Cuban's Cost Plus, and Specialty Pharmacies

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently list branded dapagliflozin, because Cost Plus primarily carries generics. Once a generic dapagliflozin reaches the U.S. Market, it may appear there at a dramatically lower price.

GoodRx prices for branded Farxiga typically range from $500 to $580 per 30-day supply, which is below list price but still substantial without assistance programs. GoodRx discounts cannot be combined with insurance or manufacturer copay cards in most cases; your pharmacist can help you compare which option is lower at the point of sale.

Some specialty pharmacies and 340B-eligible community health centers can dispense dapagliflozin at reduced cost to qualifying patients. If you receive care at a federally qualified health center (FQHC) or a 340B-covered entity, ask the pharmacy staff whether Farxiga is available through the 340B Drug Pricing Program.

Navigating Insurance Denials and Prior Authorization

Most commercial insurers and Medicare Part D plans require prior authorization (PA) for Farxiga. Common requirements include:

• Confirmed diagnosis of type 2 diabetes, heart failure, or CKD (documentation of eGFR and urine albumin-to-creatinine ratio for CKD indication)
• Trial and documented failure or intolerance of at least one lower-cost alternative (often metformin for diabetes)
• A1C above a specified threshold for the diabetes indication

If your PA is denied, your prescriber can submit an appeal. The appeal should reference the relevant clinical trial (DAPA-HF, DAPA-CKD, or DECLARE-TIMI 58) showing outcomes benefits beyond glycemic control, which is often the clinical argument that distinguishes dapagliflozin from cheaper alternatives. The DAPA-CKD trial enrolled patients with CKD regardless of diabetes status, which is a particularly strong argument for coverage in women with CKD who do not have diabetes.

If two levels of internal appeal fail, you can request an external independent review. Your state insurance commissioner's office can guide you through this process. Many external reviewers overturn denials for drugs with strong outcomes trial data.

Monitoring and Follow-Up for Women on Farxiga

Once you start dapagliflozin, routine monitoring includes:

• Renal function: Serum creatinine and eGFR at baseline, 2-4 weeks after starting, and then every 3-6 months. The drug's glycemic efficacy diminishes as eGFR falls, though cardiorenal protection continues down to lower eGFR values.
• Blood pressure: Modest BP reductions are expected; monitor for hypotension, especially if you are on diuretics or ACE inhibitors.
• Genital and urinary symptoms: Report any vulvovaginal itching, discharge, or dysuria promptly. Early treatment of candidiasis prevents it from becoming a reason to stop an otherwise beneficial medication.
• Ketones: Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious adverse event. It is more likely during prolonged fasting, surgery, very low-carbohydrate diets, or intercurrent illness. Women should hold dapagliflozin 3-4 days before any planned surgical procedure per the FDA label guidance.
• Bone density: Long-term SGLT2 inhibitor use has been associated with modest reductions in bone mineral density at the hip in some analyses, a consideration for perimenopausal and postmenopausal women who already face accelerated bone loss. Discuss baseline DEXA screening with your clinician if you are postmenopausal and starting this class of drug.

What a WomanRx Clinician Wants You to Know

"Women asking me about Farxiga access are often dealing with two problems at once: a serious cardiometabolic condition that genuinely benefits from this drug, and a healthcare system that prices it out of reach. The AZ&Me program and the copay card solve this for most of my commercially insured and low-income uninsured patients. The women who fall through the cracks are those in the Medicare donut hole or those with high-deductible plans whose copay card doesn't cover the full gap. For those patients, I document the medical necessity carefully, appeal the PA denial with trial citations, and if needed, I initiate an expanded access request directly with AstraZeneca." Maya Okafor, MD, WomanRx Editorial Board

This reflects a real clinical workflow, not a theoretical one. The most effective access strategy for Farxiga in 2026 is: copay card or AZ&Me first, PA appeal with DAPA-HF or DAPA-CKD citations second, and AstraZeneca expanded access inquiry third for cases where medical necessity is severe and other routes have failed.